Based on all above, in our study, with the goal of obtaining one excellent CAR-T product for osteosarcoma treatment, we constructed B7-H3 targeted CAR-T cells, then we evaluated anti-tumor effects of B7-H3 targeted CAR-T cells both in vitro and in vivo using the patient-derived xenografts (PDX) model of osteosarcoma. The gene discussed is CD276; the disease is neoplasm.